BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymphocytic leukemia (CLL). Results of prospective clinical trials demonstrate the efficacy of venetoclax to salvage patients with disease progression on BTKis, but data on B...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Lin, Victor S., Lew, Thomas E., Handunnetti, Sasanka M., Blombery, Piers, Nguyen, Tamia, Westerman, David A., Kuss, Bryone J., Tam, Constantine S., Roberts, Andrew W., Seymour, John F., Anderson, Mary Ann
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7316215/
https://ncbi.nlm.nih.gov/pubmed/32244251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020004782
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados